India-Oman CEPA Set To Boost Trade With Pharma Fast-Track

India and Oman are preparing to operationalize their Comprehensive Economic Partnership Agreement (CEPA) within the next three months, marking a significant milestone in bilateral relations. The agreement, finalized earlier this year, is designed to expand trade and investment flows, while offering special provisions to accelerate pharmaceutical product approvals in Oman, a move that will benefit Indian drug manufacturers.  

Key highlights from the announcement include  

• The CEPA is expected to be implemented within three months, following completion of procedural formalities.  
• Pharmaceutical approvals will be fast-tracked, reducing regulatory delays and boosting Indian pharma exports to Oman.  
• The pact covers multiple sectors including energy, manufacturing, services, and healthcare, ensuring broad-based cooperation.  
• India is Oman’s second-largest trading partner, with bilateral trade valued at over $12 billion in 2024.  
• The agreement is expected to provide Indian businesses greater access to Oman’s growing market, particularly in healthcare and infrastructure.  
• Oman will benefit from India’s expertise in pharmaceuticals, IT, and renewable energy, supporting its diversification strategy under Vision 2040.  
• Industry experts note that CEPA will strengthen supply chains, improve ease of doing business, and enhance competitiveness for both nations.  
• The fast-tracking of pharma approvals is seen as a major win for Indian exporters, who often face lengthy regulatory processes in foreign markets.  

The India-Oman CEPA reflects a broader trend of India deepening economic ties with Gulf nations, complementing existing agreements with the UAE. By focusing on sectors of mutual interest and reducing trade barriers, the pact is expected to create new opportunities for businesses while reinforcing strategic ties between the two countries.  

Sources: Economic Times, Business Standard, Moneycontrol, Reuters